We reported previously the usefulness of 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to predict prognosis of renal cell carcinoma (RCC) treated with molecular targeted agents. Herein we describe a preliminary research of nine patients who underwent FDG-PET/CT before and after initiation of nivolumab. | Early assessment with 18F-2-fluoro-2- deoxyglucose positron emission tomography computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab
